Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10 years of follow-up with localized prostate cancer treated by permanent 125iodine implants

BJU International

Volumn 106, Issue 1, 2010, Pages 32-36

  Prada, Pedro J ^a   Juan, Germán ^a   González Suárez, Herminio ^a   Fernández, José ^a   Jimenez, Isabel ^a   Amón, José ^b   Cepeda, Marcos ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

125Iodine; Brachytherapy; Morbidity; Outcome; Prostate cancer

Indexed keywords

IODINE 125; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMISTRY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RELAPSE; CANCER SURVIVAL; CATHETERIZATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FOLLOW UP; GLEASON SCORE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; IMPLANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ONCOLOGY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RADIATION DOSE; SAFETY; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; URETHRITIS; URINE RETENTION;

ADULT; AGED; AGED, 80 AND OVER; BRACHYTHERAPY; EPIDEMIOLOGIC METHODS; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77953225903     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.09096.x     Document Type: Article

References (28)

1. Mettlin CJ, Murphy GP, McDonald CJ, Menck HR. The National cancer data base report on increase use of brachytherapy for the treatment of patients with prostate carcinoma in the USA. Cancer 1999 86 : 1877 1882
2. Lee RW, Moughan J, Owen J, Zelefski MJ. The 1999 Patterns of care Study of radiotherapy in localized prostatic carcinoma. A comprehensive survey of prostate brachytherapy in the United States. Cancer 2003 98 : 1987 1994
3. Ash D, Flynn A, Battermann J, Reijke T, Lavagnini P, Blank L. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000 57 : 315 321
4. Battermann JJ, Boon TA, Moerland A. Results of permanent prostate brachytherapy, 13 years of experience at a single institution. Radiother Oncol 2004 71 : 23 8
5. Prada PJ, Juan G, Fernandez J et al. Conformal prostate brachytherapy guided by real-time dynamic dose calculation in permanent I-125 implants. Technical description and preliminary experience. Arch Esp Urol 2006 59 : 933 940
6. Fleming I, Cooper JS, Henson DE et al. AJCC Cancer Staging Manual, 5th edn.
7. Zelefsky MJ, Leibel SA, Gaudin PB et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998 41 : 491 500
8. Bice WS Prestidge BR, Prete JJ et al. Clinical impact of implementing the recommendations of AAPM Task Group 43 on permanent prostate bachytherapy using 125I. American Association of Physicists in Medicine. Int J Radiat Oncol Biol Phys 1998 40 : 1237 1241
9. Nag S, Ciezki JP, Cormack R et al. Intraoperative planning and evaluation of permanente prostate brachytherapy. Report of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 2001 51 : 1422 1430
10. Roach M, Hanks G, Thames H et al. Defining biochemical failure following radiotherapy with or without hormonal Therapy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006 65 : 965 974
11. Cox DR. Regression models and life-tables. J R Stat Soc B 1972 34 : 187
12. SPSS Inc. SPSS Manual.
13. Prada PJ, Gonzalez H, Menéndez C et al. Transperineal injection of hyaluronic acid in the anterior peri-rectal fat to decrease rectal toxicity from radiation delivered with low dose rate brachytherapy for prostate cancer patients. Brachytherapy 2009 8 : 210 217
14. Joseph J, Al-Qaisieh B, Ash D, Bottomley D, Carey B. Prostate-specific antigen relapse-free survival in patients with localized prostate cancer treated by brachytherapy. BJU Int 2004 94 : 1235 1238
15. Zelefsky MJ, Hollister T, Raben A et al. Five year biochemical outcome and toxicity with transperineal CT planned permanent iodine 125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000 47 : 1261 1266
16. Stone NS, Stock RG. 10-year biochemical and local control following real-time I-125 prostate brachytherapy. J Urol 2003 169 (Suppl.)
17. Ragde H, Elgamal AA, Snow PB et al. Ten-year disease free survival alter transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high gleason grade prostate carcinoma. Cancer 1998 83 : 989 1001
18. Grado GL, Larson TR, Balch CS et al. Actuarial disease-free survival after prostate cancer brachytherapy using interactive techniques with biplane ultrasound and fluoroscopic guidance. Int J Radiat Oncol Biol Phys 1998 42 : 289 298
19. Martinez A, Galalae R, Gonzalez J et al. No apparent benefit at five years from a course of neoadjuvant concurrent androgen deprivation for patients with prostate cáncer treated with high total radiation dose. J Urol 2003 170 : 2296 2301
20. Potters L, Torre T, Ashley R et al. Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy. J Clin Oncol 2000 6 : 1187 1192 (Pubitemid 30159835)
21. Stock RG, Stone NN, Tabert A et al. A dose-response study for iodine 125 prostate implants. Int J Radiat Oncol Biol Phys 1998 41 : 101 108
22. Potters L, Cha C, Oshinsky G et al. Risk profiles to predict PSA relapse free survival for patients undergoing permanent prostate brachytherapy. Cancer J Sci Am 1999 5 : 301 306
23. Bottomley D, Ash D, Al-Qaisieh B et al. Side effects of permanent I-125 prostate implants in 667 patients treated in Leeds. Radiother Oncol 2007 82 : 46 9
24. Gutman S, Merrick GS, Butler W et al. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent brachytherapy. BJU Int 2006 97 : 62 8
25. Henderson AS, Ismael AK, Cunnigham M et al. Toxicity and early biochemical outcomes from iodine 125 prostate brachytherapy in the UK. A prospective study. Clin Oncol 2004 16 : 95 104
26. Merrick GS, Butler WM, Galbreath RW et al. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002 52 : 893 902
27. Merrick GS, Butler WM, Wallner KE et al. Brachytherapy related dysuria. BJU Int 2005 95 : 597 602
28. Ohashi T, Yorozu A, Toya K et al. Serial changes of international prostate symptom score following I-125 prostate brachytherapy. Int J Clin Oncol 2006 11 : 320 325